President and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer Screening
Webinar to Be Held Wednesday, October 7, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open
GAITHERSBURG, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it will host an investor webinar on Wednesday, October 7, 2026, at 12:00 p.m. Eastern time.
Jonathan Cohen, President and Chief Executive Officer of 20/20 BioLabs, will discuss the September 23, 2026 meeting of the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee and what management believes the panel’s deliberations may indicate for the broader multi-cancer early detection (“MCED”) category. Mr. Cohen will also discuss the Company’s newly introduced OneTest™ franchise model, preliminary interest from laboratories across the United States, and new state funding initiatives for firefighter cancer screening.
To access the webinar, please use the following information:
Date:Wednesday, October 7, 2026Time:12:00 p.m. Eastern time (9:00 a.m. Pacific time)Webcast:Please click here to register.
During the webinar, management expects to address the following topics:
- The September 23, 2026 meeting of the FDA’s Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee, at which the panel voted favorably regarding the safety, effectiveness, and overall benefit-risk profile of GRAIL’s Galleri® MCED blood test for screening adults aged 50 years and older, and what management believes the panel’s deliberations may indicate about the FDA’s evaluation of MCED tests as a category;
- What the advisory committee vote may mean for the regulatory and reimbursement strategy 20/20 BioLabs is pursuing for OneTest™ for Cancer, including the statutory Medicare pathway for FDA-authorized MCED blood tests beginning in 2028 and the Company’s goal of achieving Medicare reimbursement for MCED by the end of 2028;
- The Company’s newly introduced OneTest™ franchise model, under which independent regional laboratories would offer OneTest™ within defined territories and verticals while 20/20 BioLabs retains ownership of its machine-learning models, patented methods, and longitudinal biomarker data;
- Preliminary interest the Company has received from laboratories across the United States and how management believes the franchise model could support broader commercial expansion without the need to build a national sales force; and
- A live question-and-answer session with management.
“The September 23 advisory committee meeting concerned another company’s test, but we believe many of the questions considered by the panel are relevant to multi-cancer early detection as a broader category,” said Jonathan Cohen, President and Chief Executive Officer of 20/20 BioLabs. “On October 7, I look forward to discussing what we believe the meeting may indicate about the regulatory path for MCED tests, where OneTest™ stands today, and how our new franchise model and growing firefighter screening programs could expand access to early cancer detection.”
The October 7 webinar is part of the Company’s monthly investor webinar series, held on the first Wednesday of each month at 12:00 p.m. Eastern time. Investors and other interested parties are encouraged to submit questions in advance to [email protected]. A replay will be made available through the Company’s investor relations website following the event.
As part of its commitment to expanding access to early cancer detection, 20/20 BioLabs will provide webinar attendees with a promotional discount code for OneTest™ at the conclusion of the event. The offer will be available to all attendees, regardless of shareholder status.
Additional detail on the Company’s business, results of operations, and risk factors is available in its filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The webinar is not expected to include the disclosure of any material non-public information.
About 20/20 BioLabs
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection blood test and OneTest™ for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s tests are designed to be affordable and accessible and can be conveniently utilized at home using new, upper-arm capillary collection devices as an alternative to traditional venipuncture. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.
For more information visit https://2020biolabs.com.
Forward-Looking Statements
Certain statements in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy, regulatory strategy, reimbursement strategy, growth strategy, acquisition strategy, and financial needs. Forward-looking statements can be identified by words such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project,” “continue,” or the negative of these terms or other comparable expressions.
Forward-looking statements in this release include, but are not limited to, statements regarding the Company’s planned investor webinar and the topics management expects to address. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including the risks described in the Company’s filings with the U.S. Securities and Exchange Commission.
There can be no assurance that the Company will complete any strategic transaction on any particular timeline, or at all. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events, except as required by applicable law.
Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
[email protected]